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Fragment based drug discoverySPR (Surface Plasmon Resonance) biosensor instru-
ments are more and more equipped to sensitively
measure the binding characteristics of small molecules
to their target. Via SPR biosensor measurements, not
only the affinity of compounds but also other features
such as the kinetics and thermodynamics aspects of
binding can be determined. Furthermore, SPR is able
to determine nonideal behavior of the fragment, such
as aggregation and poor solubility binding. The use of
SPR biosensors in various phases of the drug discovery
process is evaluated.
Introduction
Fragment-based drug design (FBDD) has become a preferred
alternative for high throughput screening (HTS) to improve
the discovery of small-molecule drug candidates. Screening
of low-molecular-weight fragments can identify hit com-
pounds with better ligand efficiencies and physiological
profiles than HTS hits. The typically lower affinities of frag-
ments initially caused concern about the ability of generat-
ing structure–activity relationships (SAR) data that are
essential for optimization, but stimulated the development
of a wealth of sensitive biophysical screening protocols. One
of these is Surface PlasmonResonance (SPR) biosensor, that is
used tomeasure not only the affinity of a compound but also*Corresponding author.: K. Retra (k.retra@few.vu.nl)
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the kinetic and even thermodynamic parameters of ligand
and fragment binding. The current generation of SPR bio-
sensor instruments has obtained the sensitivity to measure
weak fragment interactions. It is therefore one of the few
techniques that can play an important role in fragment
screening, fragment hit confirmation, characterization
and optimization.
Fragment based drug design
In fragment-based drug design (FBDD) low-molecular-weight
chemical fragments are initially selected on their ability to
bind to the target of interest or to inhibit or stimulate it in a
functional assay. Fragments can be considered as building
blocks ofmore complex drug-like compounds. The fragments
can be combined or grown into compounds. Because frag-
ments will ultimately be elaborated, they should be smaller
than typical HTS compounds. On the basis of the well known
‘rule of five’, which was proposed by Lipinski [1] to identify
‘drug-like’ compounds, a stricter ‘rule of three’ for fragments
has been proposed by Jhoti and colleagues [2]. Fragments
should have a lower molecular weight (MW < 300), be less
lipophilic (C log P  3), and the number of hydrogen bond
donors and acceptors should each be 3.
As chemical space for fragments is smaller compared
to chemical space for HTS or drug-like compounds, a few012 e181
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Table 1. Comparison summary of SPR biosensor assay formats.
SPR instrumenta Targets Pros Cons
Screening
Direct Biacore T100 [9]
Biacore S51 [5,8]
Biacore A100 [6,11]
Fuijfilm AP-3000 [10]
Hydrolase [5,6,8]
Lyase [9,10]
Direct assay compared
with a competition assay:
-No competing compound necessary
-No affinity limitations due to
competing compound
-Direct kinetic measurements
-Direct thermodynamic measurements
Direct assay compared with
a competition assay:
-High protein density
on chip necessary
-Low MW not an issueCompetition Biacore A100 [13] Hydrolase [13]
Fragment
immobilized
PlasmonImager [14,15] Hydrolase [14,15] Allows use of arrays and
therefore higher throughput
Limiting amount of
binding modes
Validation
Reference protein – Lyase [6,13]
Transferase [6,9]
Hydrolase
[6,8,13]
Fragment characterization
SAR Biacore T100 [20]
Biacore A100 [19]
Lyase [19]
Ion channel
mimic [20]
Kinetic Instrument limitations:
Kon < 5  106 M1 s1 Koff >
1  105 s1
Thermodynamic Biacore T100 [22] Ion channel mimic
[22]
Compared with ITC:
-Low protein consumption
-No new assay needed
Compared with ITC:
-Time consuming
a Mostly biacore instruments.fragments are screened in typical FBDD studies (several thou-
sand instead of amillion). The smaller size of ligands comes at
the expense of relative low binding affinities (micro to milli-
molar range). Therefore they are difficult to detect in typical
HTS assays where compound libraries are usually screened at
low micromolar concentration. One way to overcome this
liability is to screen fragments at high concentrations in
functional screening assays, however this is subject to several
pitfalls [3]. Alternatively, biophysical techniques can be used,
for example NMR, X-ray crystallography, mass-spectrometry-
based methods and Surface Plasmon Resonance (SPR) bio-
sensors [4]. The focus of this review will be on SPR biosensors.
SPR biosensors in FBDD
SPR biosensor technology is a relative young method, with
the first instrument launched in 1991. Since then there has
been a steady evolution of SPR instruments. Although Biacore
(GE Health, Uppsala, Sweden) remains market leader,
approximately 30 different manufacturers sell SPR biosensor
instruments to date. However, only a few of these instru-
ments seem to meet the high demands necessary for FBDD.
Newer instruments also have a higher throughput which is
essential for screening. Using current state-of-the-art tech-
nology, a single 384-well plate can be processed in approxi-
mately one day (384 compounds in a single concentration),e182 www.drugdiscoverytoday.commaking this approach amenable only for small libraries of
fragments. Because SPR biosensor technology is in practice a
molecular weight dependent technique, sensitive instru-
ments are essential especial for the detection of low-mole-
cular-weight compounds such as fragments. Instruments
with high sensitivity and a stable flow system, combined
withmethods to immobilize enough target protein are neces-
sary. Also data analysis should be carefully executed as the
data from SPR biosensor experiments can easily be misinter-
preted.
Figure 1a shows a schematic representation of a sensor-
gram. Shown are the association phase directly after injection
of the compound, and the dissociation phase directly after
the stop of the injection. Figure 1b shows the schematic
representation of the sensorgram of a binding fragment.
The total response at the same ligand concentration is lower
due to both a lower affinity and a lower molecular weight.
The association and dissociation rates are in general faster for
low affinity compounds. Figure 1c,d shows examples of mea-
sured sensorgrams. Note the difference between the used
concentrations, MW and affinity of the fragment (c) and
the compound grown from this fragment (d).
Most of the research described in this reviewwas performed
on instruments from Biacore (http://www.biacore.com/)
(Table 1), namely the Biacore 3000 and its successor Biacore
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Figure 1. SPR sensorgrams. Schematic representations of SPR sensorgrams of a protein–ligand interaction (a) and a protein–fragment interaction (b).
Measured SPR sensorgrams of a protein–fragment interaction (c) and a protein-grown fragment interaction.T100, or the more high throughput Biacore S51 and its
successorBiacore A100. The 3000 and T100 have a continuous
flow system with four flow channels to immobilize the target
protein, while the S51 and the A100 have four flow cells eachwith five spots for the immobilization of targets. Biacore
recently launched their new system the Biacore 4000 (an
upgrade system of the A100) which is designed for large-scale
studies of LMW compound interactions with target proteins.www.drugdiscoverytoday.com e183
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an SPR system, the Fujifilm AP-3000, which is designed
primarily as a screening platform. This instrument uses a
stopped flow system and sensor sticks that have exceptionally
high binding capacity for proteins. In conclusion, an SPR
biosensor instrument should be highly sensitive with a low S/
N to measure small molecules with low affinities. Further-
more, themeasurements should be highly reproducible and a
reasonable throughput should be reached.
Fragment lead discovery/screening
Direct binding assay
Only a handful of SPR-based fragment screens have been
published to date, although several more have been con-
ducted and presented at international conferences by phar-
maceutical companies. Surprisingly, almost all SPR screens
are conducted with enzymes from class 3 (hydrolases) or class
4 (lyase). Most probably these enzymes are good drug targets
as well as stable proteins which are easy to express, purify and
immobilize.
One of the first reported SPR biosensor-based fragment
screenings was against b-site amyloid precursor cleavage
enzyme-1 (BACE-1), a target for Alzeimer’s disease drugs;
however, the complete details of the SPR experiments
were not disclosed. The screening was conducted by the
pharmaceutical company Hoffman-La Roche, Basel, Swit-
zerland [5] and the paper describes the follow-up after the
screening.
Scientists from Biacore (GEHealth) and AstraZenica pub-
lished a SPR screening campaign against thrombin. The
manuscript describes in detail the screen of an amide library
and a general fragment library (500 fragments) [6]. Two
different concentrations were initially used for screening
of the affinities of the two libraries (200 mM and 900 mM,
respectively). The Z0 value of the 200 mM screening assay of
the amide library was 0.85, Z0 value of the other screen was
not mentioned. After discarding 18 promiscuous binders of
the general fragment library, the remaining compounds
were screened using 6-point 0–900 mM concentration series.
In total, 26 compounds fragments provided a signal of at
least 5 RU at the highest one or two concentrations, which
was used as a hit identification threshold. This indicates that
fragment libraries should indeed be screened at high con-
centrations, which might give false positives, but to a lesser
extent than in functional assays. Although the use of a
focused library such as an amide library decreases analysis
time while the success rate is maintained, it also has a
drawback as the chemical space covered is limited. A better
choice might be to screen a small fragment library which
covers the complete chemical space such as the IOTA library
(http://www.iotapharma.com/) as described by Beactica,
Sweden and the group of De Esch, VU University, The
Netherlands [7].e184 www.drugdiscoverytoday.comAt Hoffman-La Roche (Basel, Switzerland) chymase
was screened against a fragment library that consists of
2226 molecules [8]. Z0 factors were determined for four
reference compounds and between 0.54 and 0.88. In total
734 compounds showed a sensor response that was higher
than the threshold (higher than three times the standard
deviation of the negative control). By applying a selectivity
filter, the number of hits was reduced to 180 fragments
(8%).
A sophisticated SPR screening protocol was described by
Dundee University, UK [9] Carbonic anhydrase II (CAII) is
used as a model and the binding of 656 fragments is mea-
sured at three concentrations (16.6, 50, and 150 mM). The
averageZ0 for the assayswas0.63. In addition to 12 confirmed
binders, 230 false positives from the highest concentration
are present in the resulting data, indicating serious compli-
cations when measuring fragments at higher concentra-
tions.
Recently, three other publications that describe fragment
screening on SPR instruments have emerged. However, they
have different goals than finding new hit compounds. The
group of Myszka at the University of Utah tested the Fujifilm
AP-3000 for fragment screening and compared the instru-
ment with the Biacore T100 [10]. The instrument is very well
suited for fragment screening, but the stop-flow analyte
delivery system complicates the shapes of the association-
and dissociation-phase binding responses. Kreatsoulas and
Narayan fromMerck (WestPoint, USA) developed algorithms
for the automated selection of fragment-like molecules using
single-point Surface Plasmon Resonance measurements [11].
Kobayashi et al. from Zobio used target immobilization as a
strategy for NMR-based fragment screening [12]. They com-
pared two NMR screening techniques with SPR biosensor
screening.
Competition assay
At Uppsala University, Sweden, a focused fragment library
(254 compounds) was used to screen for matrix metallopro-
teinase 12 (MMP-12) inhibitors [13]. The experimental
design combined a direct binding assay with a competition
assay. The competition assay is indicative for active site
binding. For both screens fragments were injected at a
concentration of 200 mM, either alone or in mixtures with
a competitor. Twenty-three out of the 254 compounds
interacted with the target protein, 2 of these were not
competitive with an active site inhibitor, and are therefore
potential allosteric inhibitors of MMP-12. This study shows
that competition assays are key tools to identify allosteric
inhibitors. The high success rate (10%) after the first (com-
bined) screen might be a direct result of the design of the
fragment library, which contains a lot compounds with
structural similarities to S10 substituents of known MMP
inhibitors.
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Scientists from Graffinity Pharmaceuticals chose a different
setup [14,15]. They immobilized the fragments and used
proprietary SPR imaging technology to conduct High
Throughput Screening. The use of chemical microarrays in
combinationwith SPR imaging can instantly generate affinity
data for protein targets with up to 9216 immobilized frag-
ments per array. This method has therefore a higher through-
put than the other described formats and allows lowmaterial
consumption. Compounds are covalently immobilized to the
array surface via a flexible, hydrophilic spacer molecule.
Unfortunately, the linker attachment site limits the number
of possible binding modes.
Fragment hit validation
Reference proteins
Using an appropriate reference protein is essential for SPR
biosensor assays, to identify promiscuous binders and show
target specificity. An important criteria used to identify hits is
based on the difference between the signal of the target
protein and the signal of a reference protein. In general
the reference proteins are immobilized in a flow channel/
spot next to the target protein. For a system with four
channels usually one channel is left empty (uncoated dex-
tran), one is used for the target protein and two are used for
reference proteins. For a system with five immobilization
spots, a third reference protein can be added. The reference
protein should be a related protein, such as an inactive
mutant [13], a blocked target protein [6], an inactive pre-
cursor of an enzyme (zymogen) [8] or a structurally similar
protein [6,9,13].
Detection cutoff limit
Various cutoff criteria are used. For example, a detection
cutoff which is based on an average negative control signal
plus 3 standard deviations [6,8], which is usually between 2
and 10 RU. These criteria can be used in combination with
another cutoff: the adjusted response for the target protein
which should be for example 30% of the adjusted
response for the reference compound combined [13].
Because the signal is mass dependent, a cutoff of for exam-
ple 5 RU might be biased for larger fragments. To avoid
this, Ligand Efficiency (LE) can be used to set the cutoff,
for example LE = 0.333 kcal mol1 per non-hydrogen
atom [9].
Dilution series and reproducibility testing
When the primary screen has been obtained in a single
concentration, positives from a single concentration screen
should be tested again in a concentration series or in dupli-
cate or triplicate [8,9]. The SensiQ Pioneer from ICX tech-
nologies (http://www.discoversensiq.com/) is capable of
automatically generating a two- or threefold dilution series(of seven or five concentrations, respectively) from a single
analyte sample. The production of each concentrationwithin
the step gradient is highly reproducible [16]. Screening 320
compounds using the FastStep twofold dilution series
required a little over 24 hours to complete.
Competition experiments
Compounds that are tested as positives in a first screen are
usually further validated by competition experiments using
well-known inhibitors (reference compounds, usually not a
fragment) occupying (parts of) the active site [8]. A hit com-
pound that does not compete with the reference compound is
usually a false positive but might also be an allosteric binder.
Cross-competition
Cross-competition experiments between fragments can be
performed in a similar way as the competitive assay. Instead
of using a reference compound, another fragment can be used
to run the competition experiment. When fragments occupy
different pockets, the response observed should be the sum of
the two individual responses observed for the fragments [8].
Unfortunately, interpretation of the results is difficult,
because there is neither full occupancy nor full displacement
when a fragment binds.
Fragment characterization and growing
An advantage of using an SPR biosensor-based strategy is that
once an assay has been set up, it can be used both for
screening and for characterization. Usually only slight mod-
ifications in the experimental design and data analysis are
required.
Affinity ranking
Until recently SPR biosensor in drug discovery were not used
for screening but primarily for the characterization of the
hits. This technique enables defining equilibrium binding
affinities for fragments or rank them based on single point
measurements.
Fragments hits inhibiting Cyclic Amidine b-Secretase were
identified by NMR affinity screening. Thereafter they were
characterized using again NMR, but also SPR biosensor
[17,18]. An inhibition in solution assay setup was chosen.
In the SPR setup a known ligand of the target protein is
immobilized on the chip. The protein target is kept under
constant concentration and fragment hits aremixed with the
free protein thus lowering the concentration of the free
protein upon binding in a concentration-dependentmanner.
The concentration of the free protein is subsequently mea-
sured by passing the mixture over the sensor surface, which
should result in a descending signal if the fragment is com-
peting with the immobilized ligand for the binding site on
the target protein. Using just a single compound concentra-
tion, this approach enabled the scientist to obtain a fast andwww.drugdiscoverytoday.com e185
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to determine the kinetic parameters or absolute affinity for
this interaction.
SAR analysis
One of the advantages of SPR is the possibility to obtain SAR.
The compounds for this ‘analoging phase’ are often of similar
size and complexity. Synthesis of a series of hit analogs can be
combined with the expansion of the fragments to larger
compounds with higher affinity.
The SAR of proline-based inhibitors of thrombin was
explored in this way [19]. A set of 36 analogs was designed
to bind to the S2–S3 pockets of thrombin. LEs were obtained
from SPR biosensor measurements in which thrombin with a
chemically blocked active-site was used as a reference protein.
Compounds were first measured in concentration series up to
200 mM. Thereafter compounds were grouped according to
apparent affinities and reanalyzed in suitable concentration
series. Affinities up to 1 mM could be determined by using
concentration series up to 500 mM. The SPR biosensor techni-
quewasmore sensitive than an inhibition assaywith the same
target. Furthermore, it was shown that binding constants of
the SPR assaywere in good agreementwith the values from the
inhibition assay. A proposed binding mode was confirmed
with X-ray analysis and for more detailed analysis, KD values
were used for QSAR calculations. Results were obtained during
this study despite the low affinities of the compounds.
Also for the soluble acetylcholine binding protein
(AChBP), which is a homolog of the ligand-binding domain
of the nicotinic acetylcholine receptors (nAChR), SPR bio-
sensor was used to conduct LEs and SAR [20]. A focused
fragment library was generated and the interaction charac-
teristics of the fragments and the parent compounds with
AChBP were evaluated. All compounds were measured in
suitable concentration series, where the fragments with the
lowest affinity were measured in concentration series up to
100 mM. Affinities up to 0.8 mM could be detected, whereas
the standard AChBP radioligand displacement assay could
not detect these low affinity fragments. LEs for different
(structural) groups of fragments in the library were correlated
to binding with distinct regions of the binding pocket,
thereby identifying ligand efficiency hot spots (LE hot spots).
These hot spots can be used to evaluate the results of a large-
scale fragment library screen and hit selection.
Kinetic characterization of fragment hits/leads
In contrast to most methods for interaction analysis, SPR
biosensor experiments can provide the kinetic details of
interactions.
A kinetic analysis was carried out on the hits from the
MMP-12 screen described above to investigate if the fragment
interacted in a defined stoichiometric manner, as expected of
a specific interaction to a defined binding site [13]. Thee186 www.drugdiscoverytoday.comkinetic characterization also revealed differences in the inter-
action of some compounds with the mutant enzyme as
compared to that with the wild type. This indicates that
the active-site residue is directly or indirectly involved in
the interaction with the fragment.
In theory the kinetic profile can also be used to optimize
the fragment into a lead compound with a certain favorable
kinetic profile. However to the best of our knowledge no
publication exists about this. Unfortunately not all protein
targets seem to be suitable for the kinetic characterization of
their fragment hits, because kinetics might be very fast [21].
Thermodynamic characterization of fragment hits/leads
Using SPR biosensor, the changes in thermodynamic binding
profiles upon growing a fragment into a subpocket of AChBP
were explored at the VU University in Amsterdam, The
Netherlands [22]. The fragment growing design anticipates
a conformational change of the protein to open up this
subpocket. The fragment optimization process was moni-
tored using several techniques, such as X-ray analysis mole-
cular modeling and site-directed mutagenesis. All designed
compounds were measured on SPR biosensor at a suitable
concentration series and at a temperature series of 15, 20, 25,
30 and 358C. The data were analyzed via Van’t Hoff plots and
the results show that the growth into the subpocket results
from additional enthalpic interaction with the binding site.
The thermodynamic profiles obtained by SPR were in good
agreement with data from ITC experiments. There are two
main reasons to use SPR instead of ITC for obtaining the
thermodynamic profile of a fragment. First, it is not necessary
to develop a new assay format. The same assay, with some
slight modifications, can be used for screening, and (thermo-
dynamic) characterization. Second, ITC is highly protein
consuming, but SPR is not. Unfortunately, thermodynamic
characterization by SPR biosensor is rather time consuming.
Identifying nonideal behavior
SPR biosensor can be used to identify positive features of
compounds, such as high affinity and favorable thermody-
namic or kinetic profiles. It can also be used to identify
nonideal behavior such as aggregation and poor solubility
binding [23].
Non-nucleoside inhibitors of HCV NS5b RNA polymerase
were discovered by a fragment-based lead discovery
approach, beginning with crystallographic fragment screen-
ing. The NS5b binding affinity and biochemical activity of
fragment hits and inhibitors were determined by SPR and an
enzyme inhibition, respectively. The enzyme was biotiny-
lated and thereafter captured on a streptavidin surface to
obtain a density of 6000 RU. An empty streptavidin surface
was used as control surface. Although the biochemical
enzyme assay appears to be more sensitive than the SPR
enzyme assay, it gave rise to false positives that did not bind
Vol. 7, No. 3 2010 Drug Discovery Today: Technologies | Fragment based drug discoverythe enzyme. At least two of ten compounds were identified by
SPR biosensor experiments to have poor solubility, suffer
from aggregation or display nonstoichiometric binding.
The measured binding affinities were generally in agreement
with the biochemical results. Crystallographic fragment
screening hits with 1–10 mM binding affinity (measured
by SPR) were iteratively optimized to give leads with nM
biochemical activity and low mM cellular activity in the cell-
based replicon assay for HCV replication.
Conclusions
The promise of more efficient lead discovery has fuelled
enthusiasm for fragment-based approaches, accompanied by
a paradigm shift from high-throughput screening toward
design intensive approaches, enabled by structural biology.
However, this can only be accomplished with proper screen-
ing and characterization tool. SPR biosensor instruments are
more and more suitable to measure the very low affinity
compounds. Several papers show comparison between SPR
biosensor assays and other assays. In general the SPR results are
in very good agreement with the results from the more con-
ventional assays. In most cases lower affinities could be mea-
sured in the SPR assays. While in the past SPR biosensor assays
were more often used in the hit optimization and character-
ization step, nowadays the technique is also used as screening
tool. For FBDD it is one of the few techniques that can play an
important role in fragment screening, fragment hit confirma-
tion, characterization and optimization (Table 1).
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